SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) announced today that results of a Phase II clinical trial evaluating escalating doses of Neurodex™ in the treatment of painful diabetic neuropathy were published for the first time in the October issue of Clinical Therapeutics (Vol 28, Number 10, 2006). The published article “Dextromethorphan and Quinidine in Adult Patients with Uncontrolled Painful Diabetic Peripheral Neuropathy: A 29-Day, Multicenter, Open-Label, Dose-Escalation Study” indicates that the investigational new drug was well tolerated up to the highest target dose (60 mg dextromethorphan and 60 mg of quinidine dosed twice per day).
